Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.43 |
| ▸ | CA9 | Q16790 | 13/20 | 0.43 |
| ▸ | CA12 | O43570 | 10/20 | 0.43 |
| ▸ | CA1 | P00915 | 10/20 | 0.42 |
| ▸ | IKBKB | O14920 | 3/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580017 | 0.76 | SCN2A (0.63) | HPGDS | |
| SCHEMBL5597693 | 0.74 | CA12 (0.32) | CA2CA9CA12CA1IKBKB | |
| SCHEMBL8803751 | 0.66 | CA9 (0.69) | CA2CA9CA12CA1IKBKB | |
| SCHEMBL27603429 | 0.66 | CA1 (0.41) | CA2CA9CA12CA1CA4 | |
| SCHEMBL423879 | 0.64 | MASP2 (0.48) | — | |
| SCHEMBL18118200 | 0.63 | CA2 (0.60) | CA2CA9CA12CA1CA14 | |
| SCHEMBL8808134 | 0.63 | SCN2A (0.67) | HPGDS | |
| SCHEMBL18118199 | 0.62 | CA2 (0.73) | CA2CA9CA12CA1IKBKB | |
| SCHEMBL202948 | 0.62 | CA2 (0.81) | CA2CA9CA12CA1CA4 | |
| SCHEMBL18118210 | 0.62 | CA2 (0.54) | CA2CA9CA12CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504398-B2 | potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| EP-2001511-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1940408-A1 | ADENOSINE A2a RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007047293-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007038212-A1 | ADENOSINE A2a RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20060128694-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-20060106040-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | ADORA2B, ADORA2A, ADORA3 | CA2 1890/4885CA9 4154/4885CA12 4577/4885 |
| US-20060106040-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | ADORA2A, ADORA3, ADORA2B | CA2 4616/4885CA9 4883/4885CA12 4865/4885 |
| US-20060128694-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | ADORA2A, ADORA3, OPRM1 | CA2 4467/4885CA9 4881/4885CA12 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.